Animal models of Duchenne muscular dystrophy: From basic mechanisms to gene therapy

DMM Disease Models and Mechanisms

Volumn 8, Issue 3, 2015, Pages 195-213

  McGreevy, Joe W ^a   Hakim, Chady H ^a   McIntosh, Mark A ^a   Duan, Dongsheng ^a  

^a University of Missouri   (United States)

Author keywords

Animal model; Canine DMD; Duchenne muscular dystrophy; Dystrophin; Gene therapy

Indexed keywords

DYSTROPHIN; VIRUS VECTOR;

ANIMAL MODEL; CANINE MODEL; CLINICAL FEATURE; COGNITIVE DEFECT; CONGESTIVE CARDIOMYOPATHY; DISEASE SEVERITY; DUCHENNE MUSCULAR DYSTROPHY; EXON; GENE MUTATION; GENE REPLACEMENT THERAPY; GENE THERAPY; GENETIC ENGINEERING; HUMAN; MOUSE MODEL; MYOPATHY; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; REVIEW; ANIMAL; CARDIOMYOPATHIES; DEFICIENCY; DISEASE MODEL; METABOLISM; MUSCULAR DYSTROPHY, DUCHENNE; NERVE CELL; PATHOLOGY;

ANIMALIA; CANIS FAMILIARIS; INVERTEBRATA; MAMMALIA; MUS;

ANIMALS; CARDIOMYOPATHIES; DISEASE MODELS, ANIMAL; DYSTROPHIN; GENETIC THERAPY; MUSCULAR DYSTROPHY, DUCHENNE; NEURONS;

EID: 84929145979     PISSN: 17548403     EISSN: 17548411     Source Type: Journal    
DOI: 10.1242/dmm.018424     Document Type: Review

References (348)

1. Aartsma-Rus, A. (2012). Overview on DMD exon skipping. Methods Mol. Biol. 867, 97-116.
2. Aartsma-Rus, A., Van Deutekom, J. C., Fokkema, I. F., Van Ommen, G. J. and Den Dunnen, J. T. (2006). Entries in the Leiden Duchenne muscular dystrophy mutation database: an overview of mutation types and paradoxical cases that confirm the reading-frame rule. Muscle Nerve 34, 135-144.
3. Acsadi, G., Dickson, G., Love, D. R., Jani, A., Walsh, F. S., Gurusinghe, A., Wolff, J. A. and Davies, K. E. (1991). Human dystrophin expression in mdx mice after intramuscular injection of DNA constructs. Nature 352, 815-818.
4. Ahn, A. H. and Kunkel, L. M. (1993). The structural and functional diversity of dystrophin. Nat. Genet. 3, 283-291.
5. Aigner, B., Rathkolb, B., Klaften, M., Sedlmeier, R., Klempt, M., Wagner, S., Michel, D., Mayer, U., Klopstock, T., de Angelis, M. H. et al. (2009). Generation of N-ethyl-N-nitrosourea-induced mouse mutants with deviations in plasma enzyme activities as novel organ-specific disease models. Exp. Physiol. 94, 412-421.
6. Akkaraju, G. R., Huard, J., Hoffman, E. P., Goins, W. F., Pruchnic, R., Watkins, S. C., Cohen, J. B. and Glorioso, J. C. (1999). Herpes simplex virus vector-mediated dystrophin gene transfer and expression in mdx mouse skeletal muscle. J. Gene Med. 1, 280-289.
7. Alter, J., Lou, F., Rabinowitz, A., Yin, H., Rosenfeld, J., Wilton, S. D., Partridge, T. A. and Lu, Q. L. (2006). Systemic delivery of morpholino oligonucleotide restores dystrophin expression bodywide and improves dystrophic pathology. Nat. Med. 12, 175-177.
8. Ambrósio, C. E., Valadares, M. C., Zucconi, E., Cabral, R., Pearson, P. L., Gaiad, T. P., Canovas, M., Vainzof, M., Miglino, M. A. and Zatz, M. (2008). Ringo, a Golden Retriever Muscular Dystrophy (GRMD) dog with absent dystrophin but normal strength. Neuromuscul. Disord. 18, 892-893.
9. Anderson, J. L., Head, S. I., Rae, C. and Morley, J. W. (2002). Brain function in Duchenne muscular dystrophy. Brain 125, 4-13.
10. Aoki, Y., Yokota, T., Nagata, T., Nakamura, A., Tanihata, J., Saito, T., Duguez, S. M., Nagaraju, K., Hoffman, E. P., Partridge, T. et al. (2012). Bodywide skipping of exons 45-55 in dystrophic mdx52 mice by systemic antisense delivery. Proc. Natl. Acad. Sci. USA 109, 13763-13768.
11. Ardite, E., Perdiguero, E., Vidal, B., Gutarra, S., Serrano, A. L. and Muñoz-Cánoves, P. (2012). PAI-1-regulated miR-21 defines a novel age-associated fibrogenic pathway in muscular dystrophy. J. Cell Biol. 196, 163-175.
12. Arpke, R. W., Darabi, R., Mader, T. L., Zhang, Y., Toyama, A., Lonetree, C. L., Nash, N., Lowe, D. A., Perlingeiro, R. C. and Kyba, M. (2013). A new immuno-, dystrophin-deficient model, the NSG-mdx4cv mouse, provides evidence for functional improvement following allogeneic satellite cell transplantation. Stem Cells 31, 1611-1620.
13. Ashwath, M. L., Jacobs, I. B., Crowe, C. A., Ashwath, R. C., Super, D. M. and Bahler, R. C. (2014). Left ventricular dysfunction in Duchenne muscular dystrophy and genotype. Am. J. Cardiol. 114, 284-289.
14. Atencia-Fernandez, S., Shiel, R. E., Mooney, C. T. and Nolan, C. M. (2015). Muscular dystrophy in the Japanese Spitz: an inversion disrupts the DMD and RPGR genes. Anim. Genet. [Epub ahead of print] doi: 10.1111/age.12266.
15. Banks, G. B., Judge, L. M., Allen, J. M. and Chamberlain, J. S. (2010). The polyproline site in hinge 2 influences the functional capacity of truncated dystrophins. PLoS Genet. 6, e1000958.
16. Banks, G. B., Combs, A. C., Odom, G. L., Bloch, R. J. and Chamberlain, J. S. (2014). Muscle structure influences utrophin expression in mdx mice. PLoS Genet. 10, e1004431.
17. Barbash, I. M., Cecchini, S., Faranesh, A. Z., Virag, T., Li, L., Yang, Y., Hoyt, R. F., Kornegay, J. N., Bogan, J. R., Garcia, L. et al. (2013). MRI roadmap-guided transendocardial delivery of exon-skipping recombinant adeno-associated virus restores dystrophin expression in a canine model of Duchenne muscular dystrophy. Gene Ther. 20, 274-282.
18. Bardoni, A., Sironi, M., Felisari, G., Comi, G. P. and Bresolin, N. (1999). Absence of brain Dp140 isoform and cognitive impairment in Becker muscular dystrophy. Lancet 353, 897-898.
19. Bardoni, A., Felisari, G., Sironi, M., Comi, G., Lai, M., Robotti, M. and Bresolin, N. (2000). Loss of Dp140 regulatory sequences is associated with cognitive impairment in dystrophinopathies. Neuromuscul. Disord. 10, 194-199.
20. Bartlett, R. J., Stockinger, S., Denis, M. M., Bartlett, W. T., Inverardi, L., Le, T. T., thi Man, N., Morris, G. E., Bogan, D. J., Metcalf-Bogan, J. et al. (2000). In vivo targeted repair of a point mutation in the canine dystrophin gene by a chimeric RNA/DNA oligonucleotide. Nat. Biotechnol. 18, 615-622.
21. Beastrom, N., Lu, H., Macke, A., Canan, B. D., Johnson, E. K., Penton, C. M., Kaspar, B. K., Rodino-Klapac, L. R., Zhou, L., Janssen, P. M. et al. (2011). Mdx5cv mice manifest more severe muscle dysfunction and diaphragm force deficits than do mdx Mice. Am. J. Pathol. 179, 2464-2474.
22. Beggs, A. H., Hoffman, E. P., Snyder, J. R., Arahata, K., Specht, L., Shapiro, F., Angelini, C., Sugita, H. and Kunkel, L. M. (1991). Exploring the molecular basis for variability among patients with Becker muscular dystrophy: dystrophin gene and protein studies. Am. J. Hum. Genet. 49, 54-67.
23. Bencze, M., Negroni, E., Vallese, D., Yacoub-Youssef, H., Chaouch, S., Wolff, A., Aamiri, A., Di Santo, J. P., Chazaud, B., Butler-Browne, G. et al. (2012). Proinflammatory macrophages enhance the regenerative capacity of human myoblasts by modifying their kinetics of proliferation and differentiation. Mol. Ther. 20, 2168-2179.
24. Berger, J. and Currie, P. D. (2012). Zebrafish models flex their muscles to shed light on muscular dystrophies. Dis. Model. Mech. 5, 726-732.
25. Bertoni, C. (2014). Emerging gene editing strategies for Duchenne muscular dystrophy targeting stem cells. Front. Physiol. 5, 148.
26. Bish, L. T., Sleeper, M. M., Forbes, S. C., Wang, B., Reynolds, C., Singletary, G. E., Trafny, D., Morine, K. J., Sanmiguel, J., Cecchini, S. et al. (2012). Long-term restoration of cardiac dystrophin expression in golden retriever muscular dystrophy following rAAV6-mediated exon skipping. Mol. Ther. 20, 580-589.
27. Blake, D. J., Weir, A., Newey, S. E. and Davies, K. E. (2002). Function and genetics of dystrophin and dystrophin-related proteins in muscle. Physiol. Rev. 82, 291-329.
28. Bonilla, E., Samitt, C. E., Miranda, A. F., Hays, A. P., Salviati, G., DiMauro, S., Kunkel, L. M., Hoffman, E. P. and Rowland, L. P. (1988). Duchenne muscular dystrophy: deficiency of dystrophin at the muscle cell surface. Cell 54, 447-452.
29. Bostick, B., Ghosh, A., Yue, Y., Long, C. and Duan, D. (2007). Systemic AAV-9 transduction in mice is influenced by animal age but not by the route of administration. Gene Ther. 14, 1605-1609.
30. Bostick, B., Yue, Y., Lai, Y., Long, C., Li, D. and Duan, D. (2008a). Adeno-associated virus serotype-9 microdystrophin gene therapy ameliorates electrocardiographic abnormalities in mdx mice. Hum. Gene Ther. 19, 851-856.
31. Bostick, B., Yue, Y., Long, C. and Duan, D. (2008b). Prevention of dystrophindeficient cardiomyopathy in twenty-one-month-old carrier mice by mosaic dystrophin expression or complementary dystrophin/utrophin expression. Circ. Res. 102, 121-130.
32. Bostick, B., Yue, Y., Long, C., Marschalk, N., Fine, D. M., Chen, J. and Duan, D. (2009). Cardiac expression of a mini-dystrophin that normalizes skeletal muscle force only partially restores heart function in aged mdx mice. Mol. Ther. 17, 253-261.
33. Bostick, B., Yue, Y. and Duan, D. (2010). Gender influences cardiac function in the mdx model of Duchenne cardiomyopathy. Muscle Nerve 42, 600-603.
34. Bostick, B., Shin, J.-H., Yue, Y. and Duan, D. (2011). AAV-microdystrophin therapy improves cardiac performance in aged female mdx mice. Mol. Ther. 19, 1826-1832.
35. Bostick, B., Shin, J. H., Yue, Y., Wasala, N. B., Lai, Y. and Duan, D. (2012). AAV micro-dystrophin gene therapy alleviates stress-induced cardiac death but not myocardial fibrosis in >21-m-old mdx mice, an end-stage model of Duchenne muscular dystrophy cardiomyopathy. J. Mol. Cell. Cardiol. 53, 217-222.
36. Braun, S. (2004). Naked plasmid DNA for the treatment of muscular dystrophy. Curr. Opin. Mol. Ther. 6, 499-505.
37. Bulfield, G., Siller, W. G., Wight, P. A. and Moore, K. J. (1984). X chromosome-linked muscular dystrophy (mdx) in the mouse. Proc. Natl. Acad. Sci. USA 81, 1189-1192.
38. Bulman, D. E., Murphy, E. G., Zubrzycka-Gaarn, E. E., Worton, R. G. and Ray, P. N. (1991). Differentiation of Duchenne and Becker muscular dystrophy phenotypes with amino- and carboxy-terminal antisera specific for dystrophin. Am. J. Hum. Genet. 48, 295-304.
39. Burkin, D. J., Wallace, G. Q., Nicol, K. J., Kaufman, D. J. and Kaufman, S. J. (2001). Enhanced expression of the alpha 7 beta 1 integrin reduces muscular dystrophy and restores viability in dystrophic mice. J. Cell Biol. 152, 1207-1218.
40. Burkin, D. J., Wallace, G. Q., Milner, D. J., Chaney, E. J., Mulligan, J. A. and Kaufman, S. J. (2005). Transgenic expression of alpha7beta1 integrin maintains muscle integrity, increases regenerative capacity, promotes hypertrophy, and reduces cardiomyopathy in dystrophic mice. Am. J. Pathol. 166, 253-263.
41. Bushby, K. and Connor, E. (2011). Clinical outcome measures for trials in Duchenne muscular dystrophy: report from International Working Group meetings. Clin. Investig. (Lond) 1, 1217-1235.
42. Byers, T. J., Neumann, P. E., Beggs, A. H. and Kunkel, L. M. (1992). ELISA quantitation of dystrophin for the diagnosis of Duchenne and Becker muscular dystrophies. Neurology 42, 570-576.
43. Cerletti, M., Negri, T., Cozzi, F., Colpo, R., Andreetta, F., Croci, D., Davies, K. E., Cornelio, F., Pozza, O., Karpati, G. et al. (2003). Dystrophic phenotype of canine X-linked muscular dystrophy is mitigated by adenovirus-mediated utrophin gene transfer. Gene Ther. 10, 750-757.
44. Chamberlain, J. S. (2002). Gene therapy of muscular dystrophy. Hum. Mol. Genet. 11, 2355-2362.
45. Chamberlain, J. S. and Benian, G. M. (2000). Muscular dystrophy: the worm turns to genetic disease. Curr. Biol. 10, R795-R797.
46. Chamberlain, J. S., Metzger, J., Reyes, M., Townsend, D. and Faulkner, J. A. (2007). Dystrophin-deficient mdx mice display a reduced life span and are susceptible to spontaneous rhabdomyosarcoma. FASEB J. 21, 2195-2204.
47. Chandrasekharan, K., Yoon, J. H., Xu, Y., deVries, S., Camboni, M., Janssen, P. M., Varki, A. and Martin, P. T. (2010). A human-specific deletion in mouse Cmah increases disease severity in the mdx model of Duchenne muscular dystrophy. Sci. Transl. Med. 2, 42ra54.
48. Chapdelaine, P., Pichavant, C., Rousseau, J., Pâques, F. and Tremblay, J. P. (2010). Meganucleases can restore the reading frame of a mutated dystrophin. Gene Ther. 17, 846-858.
49. Chapman, V. M., Miller, D. R., Armstrong, D. and Caskey, C. T. (1989). Recovery of induced mutations for X chromosome-linked muscular dystrophy in mice. Proc. Natl. Acad. Sci. USA 86, 1292-1296.
50. Cirak, S., Arechavala-Gomeza, V., Guglieri, M., Feng, L., Torelli, S., Anthony, K., Abbs, S., Garralda, M. E., Bourke, J., Wells, D. J. et al. (2011). Exon skipping and dystrophin restoration in patients with Duchenne muscular dystrophy after systemic phosphorodiamidate morpholino oligomer treatment: an open-label, phase 2, dose-escalation study. Lancet 378, 595-605.
51. Clemens, P. R., Kochanek, S., Sunada, Y., Chan, S., Chen, H. H., Campbell, K. P. and Caskey, C. T. (1996). In vivo muscle gene transfer of full-length dystrophin with an adenoviral vector that lacks all viral genes. Gene Ther. 3, 965-972.
52. Cooper, B. J., Valentine, B. A., Wilson, S., Patterson, D. F. and Concannon, P. W. (1988a). Canine muscular dystrophy: confirmation of X-linked inheritance. J. Hered. 79, 405-408.
53. Cooper, B. J., Winand, N. J., Stedman, H., Valentine, B. A., Hoffman, E. P., Kunkel, L. M., Scott, M. O., Fischbeck, K. H., Kornegay, J. N., Avery, R. J. et al. (1988b). The homologue of the Duchenne locus is defective in X-linked muscular dystrophy of dogs. Nature 334, 154-156.
54. Cooper, B. J., Gallagher, E. A., Smith, C. A., Valentine, B. A. and Winand, N. J. (1990). Mosaic expression of dystrophin in carriers of canine X-linked muscular dystrophy. Lab. Invest. 62, 171-178.
55. Cotten, S. W., Kornegay, J. N., Bogan, D. J., Wadosky, K. M., Patterson, C. and Willis, M. S. (2013). Genetic myostatin decrease in the golden retriever muscular dystrophy model does not significantly affect the ubiquitin proteasome system despite enhancing the severity of disease. Am. J. Transl. Res. 6, 43-53.
56. Cox, G. A., Cole, N. M., Matsumura, K., Phelps, S. F., Hauschka, S. D., Campbell, K. P., Faulkner, J. A. and Chamberlain, J. S. (1993a). Overexpression of dystrophin in transgenic mdx mice eliminates dystrophic symptoms without toxicity. Nature 364, 725-729.
57. Cox, G. A., Phelps, S. F., Chapman, V. M. and Chamberlain, J. S. (1993b). New mdx mutation disrupts expression of muscle and nonmuscle isoforms of dystrophin. Nat. Genet. 4, 87-93.
58. Cox, G. A., Sunada, Y., Campbell, K. P. and Chamberlain, J. S. (1994). Dp71 can restore the dystrophin-associated glycoprotein complex in muscle but fails to prevent dystrophy. Nat. Genet. 8, 333-339.
59. Cozzi, F., Cerletti, M., Luvoni, G. C., Lombardo, R., Brambilla, P. G., Faverzani, S., Blasevich, F., Cornelio, F., Pozza, O. and Mora, M. (2001). Development of muscle pathology in canine X-linked muscular dystrophy. II. Quantitative characterization of histopathological progression during postnatal skeletal muscle development. Acta Neuropathol. 101, 469-478.
60. Crawford, G. E., Faulkner, J. A., Crosbie, R. H., Campbell, K. P., Froehner, S. C. and Chamberlain, J. S. (2000). Assembly of the dystrophin-associated protein complex does not require the dystrophin COOH-terminal domain. J. Cell Biol. 150, 1399-1410.
61. Crisp, A., Yin, H., Goyenvalle, A., Betts, C., Moulton, H. M., Seow, Y., Babbs, A., Merritt, T., Saleh, A. F., Gait, M. J. et al. (2011). Diaphragm rescue alone prevents heart dysfunction in dystrophic mice. Hum. Mol. Genet. 20, 413-421.
62. D'Angelo, M. G. and Bresolin, N. (2006). Cognitive impairment in neuromuscular disorders. Muscle Nerve 34, 16-33.
63. Dallérac, G., Perronnet, C., Chagneau, C., Leblanc-Veyrac, P., Samson-Desvignes, N., Peltekian, E., Danos, O., Garcia, L., Laroche, S., Billard, J. M. et al. (2011). Rescue of a dystrophin-like protein by exon skipping normalizes synaptic plasticity in the hippocampus of the mdx mouse. Neurobiol. Dis. 43, 635-641.
64. Danko, I., Chapman, V. and Wolff, J. A. (1992). The frequency of revertants in mdx mouse genetic models for Duchenne muscular dystrophy. Pediatr. Res. 32, 128-131.
65. Daoud, F., Angeard, N., Demerre, B., Martie, I., Benyaou, R., Leturcq, F., Cossée, M., Deburgrave, N., Saillour, Y., Tuffery, S. et al. (2009a). Analysis of Dp71 contribution in the severity of mental retardation through comparison of Duchenne and Becker patients differing by mutation consequences on Dp71 expression. Hum. Mol. Genet. 18, 3779-3794.
66. Daoud, F., Candelario-Martínez, A., Billard, J. M., Avital, A., Khelfaoui, M., Rozenvald, Y., Guegan, M., Mornet, D., Jaillard, D., Nudel, U. et al. (2009b). Role of mental retardation-associated dystrophin-gene product Dp71 in excitatory synapse organization, synaptic plasticity and behavioral functions. PLoS ONE 4, e6574.
67. Decary, S., Hamida, C. B., Mouly, V., Barbet, J. P., Hentati, F. and Butler-Browne, G. S. (2000). Shorter telomeres in dystrophic muscle consistent with extensive regeneration in young children. Neuromuscul. Disord. 10, 113-120.
68. Deconinck, A. E., Rafael, J. A., Skinner, J. A., Brown, S. C., Potter, A. C., Metzinger, L., Watt, D. J., Dickson, J. G., Tinsley, J. M. and Davies, K. E. (1997a). Utrophin-dystrophin-deficient mice as a model for Duchenne muscular dystrophy. Cell 90, 717-727.
69. Deconinck, N., Tinsley, J., De Backer, F., Fisher, R., Kahn, D., Phelps, S., Davies, K. and Gillis, J. M. (1997b). Expression of truncated utrophin leads to major functional improvements in dystrophin-deficient muscles of mice. Nat. Med. 3, 1216-1221.
70. DelloRusso, C., Scott, J. M., Hartigan-O'Connor, D., Salvatori, G., Barjot, C., Robinson, A. S., Crawford, R. W., Brooks, S. V. and Chamberlain, J. S. (2002). Functional correction of adult mdx mouse muscle using gutted adenoviral vectors expressing full-length dystrophin. Proc. Natl. Acad. Sci. USA 99, 12979-12984.
71. Denti, M. A., Rosa, A., D'Antona, G., Sthandier, O., De Angelis, F. G., Nicoletti, C., Allocca, M., Pansarasa, O., Parente, V., Musarò, A. et al. (2006). Body-wide gene therapy of Duchenne muscular dystrophy in the mdx mouse model. Proc. Natl. Acad. Sci. USA 103, 3758-3763.
72. Deol, J. R., Danialou, G., Larochelle, N., Bourget, M., Moon, J. S., Liu, A. B., Gilbert, R., Petrof, B. J., Nalbantoglu, J. and Karpati, G. (2007). Successful compensation for dystrophin deficiency by a helper-dependent adenovirus expressing full-length utrophin. Mol. Ther. 15, 1767-1774.
73. Desguerre, I., Christov, C., Mayer, M., Zeller, R., Becane, H. M., Bastuji-Garin, S., Leturcq, F., Chiron, C., Chelly, J. and Gherardi, R. K. (2009). Clinical heterogeneity of duchenne muscular dystrophy (DMD): definition of sub-phenotypes and predictive criteria by long-term follow-up. PLoS ONE 4, e4347.
74. Duan, D. (2006). Challenges and opportunities in dystrophin-deficient cardiomyopathy gene therapy. Hum. Mol. Genet. 15, R253-R261.
75. Duan, D. (2008). Myodys, a full-length dystrophin plasmid vector for Duchenne and Becker muscular dystrophy gene therapy. Curr. Opin. Mol. Ther. 10, 86-94.
76. Duan, D. (2011). Duchenne muscular dystrophy gene therapy: lost in translation? Res. Rep. Biol. 2011, 31-42.
77. Duan, D. (2015). Duchenne muscular dystrophy gene therapy in the canine model. Hum. Gene Ther. Clin. Dev. [Epub ahead of print] doi:10.1089/hum.2015.006.
78. Duan, D., Hakim, C. H., Ambrosio, C. E., Smith, B. F. and Sweeney, H. L. (2015). Early loss of ambulation is not a representative clinical feature in Duchenne muscular dystrophy dogs: remarks on the article of Barthélémy et al. Dis. Model. Mech. 8, 193-194.
79. Dubowitz, V. (2006). Enigmatic conflict of clinical and molecular diagnosis in Duchenne/Becker muscular dystrophy. Neuromuscul. Disord. 16, 865-866.
80. Dunckley, M. G., Wells, D. J., Walsh, F. S. and Dickson, G. (1993). Direct retroviral-mediated transfer of a dystrophin minigene into mdx mouse muscle in vivo. Hum. Mol. Genet. 2, 717-723.
81. Dunckley, M. G., Manoharan, M., Villiet, P., Eperon, I. C. and Dickson, G. (1998). Modification of splicing in the dystrophin gene in cultured mdx muscle cells by antisense oligoribonucleotides. Hum. Mol. Genet. 7, 1083-1090.
82. Ebihara, S., Guibinga, G. H., Gilbert, R., Nalbantoglu, J., Massie, B., Karpati, G. and Petrof, B. J. (2000). Differential effects of dystrophin and utrophin gene transfer in immunocompetent muscular dystrophy (mdx) mice. Physiol. Genomics 3, 133-144.
83. Emery, A. E. H. and Muntoni, F. (2003). Duchenne muscular dystrophy. Oxford; New York, NY: Oxford University Press.
84. England, S. B., Nicholson, L. V., Johnson, M. A., Forrest, S. M., Love, D. R., Zubrzycka-Gaarn, E. E., Bulman, D. E., Harris, J. B. and Davies, K. E. (1990). Very mild muscular dystrophy associated with the deletion of 46% of dystrophin. Nature 343, 180-182.
85. Ervasti, J. M. (2007). Dystrophin, its interactions with other proteins, and implications for muscular dystrophy. Biochim. Biophys. Acta 1772, 108-117.
86. Fan, Z., Wang, J., Ahn, M., Shiloh-Malawsky, Y., Chahin, N., Elmore, S., Bagnell, C. R., Jr, Wilber, K., An, H., Lin, W. et al. (2014). Characteristics of magnetic resonance imaging biomarkers in a natural history study of golden retriever muscular dystrophy. Neuromuscul. Disord. 24, 178-191.
87. Farini, A., Meregalli, M., Belicchi, M., Battistelli, M., Parolini, D., D'Antona, G., Gavina, M., Ottoboni, L., Constantin, G., Bottinelli, R. et al. (2007). T and B lymphocyte depletion has a marked effect on the fibrosis of dystrophic skeletal muscles in the scid/mdx mouse. J. Pathol. 213, 229-238.
88. Felisari, G., Martinelli Boneschi, F., Bardoni, A., Sironi, M., Comi, G. P., Robotti, M., Turconi, A. C., Lai, M., Corrao, G. and Bresolin, N. (2000). Loss of Dp140 dystrophin isoform and intellectual impairment in Duchenne dystrophy. Neurology 55, 559-564.
89. Ferreiro, V., Giliberto, F., Muñiz, G. M., Francipane, L., Marzese, D. M., Mampel, A., Roqué, M., Frechtel, G. D. and Szijan, I. (2009). Asymptomatic Becker muscular dystrophy in a family with a multiexon deletion. Muscle Nerve 39, 239-243.
90. Fine, D. M., Shin, J. H., Yue, Y., Volkmann, D., Leach, S. B., Smith, B. F., McIntosh, M. and Duan, D. (2011). Age-matched comparison reveals early electrocardiography and echocardiography changes in dystrophin-deficient dogs. Neuromuscul. Disord. 21, 453-461.
91. Finsterer, J. and Cripe, L. (2014). Treatment of dystrophin cardiomyopathies. Nat. Rev. Cardiol. 11, 168-179.
92. Flanigan, K. M., Dunn, D. M., von Niederhausern, A., Howard, M. T., Mendell, J., Connolly, A., Saunders, C., Modrcin, A., Dasouki, M., Comi, G. P. et al. (2009a). DMD Trp3X nonsense mutation associated with a founder effect in North American families with mild Becker muscular dystrophy. Neuromuscul. Disord. 19, 743-748.
93. Flanigan, K. M., Dunn, D. M., von Niederhausern, A., Soltanzadeh, P., Gappmaier, E., Howard, M. T., Sampson, J. B., Mendell, J. R., Wall, C., King, W. M. et al.; United Dystrophinopathy Project Consortium (2009b). Mutational spectrum of DMD mutations in dystrophinopathy patients: application of modern diagnostic techniques to a large cohort. Hum. Mutat. 30, 1657-1666.
94. Foster, H., Sharp, P. S., Athanasopoulos, T., Trollet, C., Graham, I. R., Foster, K., Wells, D. J. and Dickson, G. (2008). Codon and mRNA sequence optimization of microdystrophin transgenes improves expression and physiological outcome in dystrophic mdx mice following AAV2/8 gene transfer. Mol. Ther. 16, 1825-1832.
95. Fujimoto, T., Itoh, K., Yaoi, T. and Fushiki, S. (2014). Somatodendritic and excitatory postsynaptic distribution of neuron-type dystrophin isoform, Dp40, in hippocampal neurons. Biochem. Biophys. Res. Commun. 452, 79-84.
96. Fukada, S., Morikawa, D., Yamamoto, Y., Yoshida, T., Sumie, N., Yamaguchi, M., Ito, T., Miyagoe-Suzuki, Y., Takeda, S., Tsujikawa, K. et al. (2010). Genetic background affects properties of satellite cells and mdx phenotypes. Am. J. Pathol. 176, 2414-2424.
97. Funkquist, B., Haraldsson, I. and Stahre, L. (1980). Primary progressive muscular dystrophy in the dog. Vet. Rec. 106, 341-343.
98. Gaedigk, R., Law, D. J., Fitzgerald-Gustafson, K. M., McNulty, S. G., Nsumu, N. N., Modrcin, A. C., Rinaldi, R. J., Pinson, D., Fowler, S. C., Bilgen, M. et al. (2006). Improvement in survival and muscle function in an mdx/utrn(-/-) double mutant mouse using a human retinal dystrophin transgene. Neuromuscul. Disord. 16, 192-203.
99. Gao, G. P., Alvira, M. R., Wang, L., Calcedo, R., Johnston, J. and Wilson, J. M. (2002). Novel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy. Proc. Natl. Acad. Sci. USA 99, 11854-11859.
100. Gawlik, K. I., Holmberg, J. and Durbeej, M. (2014). Loss of dystrophin and β-sarcoglycan significantly exacerbates the phenotype of laminin α2 chain-deficient animals. Am. J. Pathol. 184, 740-752.
101. Gebski, B. L., Mann, C. J., Fletcher, S. and Wilton, S. D. (2003). Morpholino antisense oligonucleotide induced dystrophin exon 23 skipping in mdx mouse muscle. Hum. Mol. Genet. 12, 1801-1811.
102. Ghedini, P. C., Avellar, M. C., De Lima, T. C., Lima-Landman, M. T., Lapa, A. J. and Souccar, C. (2012). Quantitative changes of nicotinic receptors in the hippocampus of dystrophin-deficient mice. Brain Res. 1483, 96-104.
103. Ghosh, A., Yue, Y., Lai, Y. and Duan, D. (2008). A hybrid vector system expands adeno-associated viral vector packaging capacity in a transgene-independent manner. Mol. Ther. 16, 124-130.
104. Gilbert, R., Nalbantoglu, J., Petrof, B. J., Ebihara, S., Guibinga, G. H., Tinsley, J. M., Kamen, A., Massie, B., Davies, K. E. and Karpati, G. (1999). Adenovirus-mediated utrophin gene transfer mitigates the dystrophic phenotype of mdx mouse muscles. Hum. Gene Ther. 10, 1299-1310.
105. Goemans, N. M., Tulinius, M., van den Akker, J. T., Burm, B. E., Ekhart, P. F., Heuvelmans, N., Holling, T., Janson, A. A., Platenburg, G. J., Sipkens, J. A. et al. (2011). Systemic administration of PRO051 in Duchenne's muscular dystrophy. N. Engl. J. Med. 364, 1513-1522.
106. Goyenvalle, A., Vulin, A., Fougerousse, F., Leturcq, F., Kaplan, J. C., Garcia, L. and Danos, O. (2004). Rescue of dystrophic muscle through U7 snRNA-mediated exon skipping. Science 306, 1796-1799.
107. Goyenvalle, A., Seto, J. T., Davies, K. E. and Chamberlain, J. (2011). Therapeutic approaches to muscular dystrophy. Hum. Mol. Genet. 20, R69-R78.
108. Goyenvalle, A., Babbs, A., Wright, J., Wilkins, V., Powell, D., Garcia, L. and Davies, K. E. (2012). Rescue of severely affected dystrophin/utrophin-deficient mice through scAAV-U7snRNA-mediated exon skipping. Hum. Mol. Genet. 21, 2559-2571.
109. Graciotti, L., Minelli, A., Minciacchi, D., Procopio, A. and Fulgenzi, G. (2008). GABAergic miniature spontaneous activity is increased in the CA1 hippocampal region of dystrophic mdx mice. Neuromuscul. Disord. 18, 220-226.
110. Grady, R. M., Teng, H., Nichol, M. C., Cunningham, J. C., Wilkinson, R. S. and Sanes, J. R. (1997). Skeletal and cardiac myopathies in mice lacking utrophin and dystrophin: a model for Duchenne muscular dystrophy. Cell 90, 729-738.
111. Grady, R. M., Grange, R. W., Lau, K. S., Maimone, M. M., Nichol, M. C., Stull, J. T. and Sanes, J. R. (1999). Role for alpha-dystrobrevin in the pathogenesis of dystrophin-dependent muscular dystrophies. Nat. Cell Biol. 1, 215-220.
112. Greenberg, D. S., Sunada, Y., Campbell, K. P., Yaffe, D. and Nudel, U. (1994). Exogenous Dp71 restores the levels of dystrophin associated proteins but does not alleviate muscle damage in mdx mice. Nat. Genet. 8, 340-344.
113. Gregorevic, P., Blankinship, M. J., Allen, J. M., Crawford, R. W., Meuse, L., Miller, D. G., Russell, D. W. and Chamberlain, J. S. (2004). Systemic delivery of genes to striated muscles using adeno-associated viral vectors. Nat. Med. 10, 828-834.
114. Gregorevic, P., Allen, J. M., Minami, E., Blankinship, M. J., Haraguchi, M., Meuse, L., Finn, E., Adams, M. E., Froehner, S. C., Murry, C. E. et al. (2006). rAAV6- microdystrophin preserves muscle function and extends lifespan in severely dystrophic mice. Nat. Med. 12, 787-789.
115. Guo, C., Willem, M., Werner, A., Raivich, G., Emerson, M., Neyses, L. and Mayer, U. (2006). Absence of alpha 7 integrin in dystrophin-deficient mice causes a myopathy similar to Duchenne muscular dystrophy. Hum. Mol. Genet. 15, 989-998.
116. Haecker, S. E., Stedman, H. H., Balice-Gordon, R. J., Smith, D. B., Greelish, J. P., Mitchell, M. A., Wells, A., Sweeney, H. L. and Wilson, J. M. (1996). In vivo expression of full-length human dystrophin from adenoviral vectors deleted of all viral genes. Hum. Gene Ther. 7, 1907-1914.
117. Hakim, C. H. and Duan, D. (2013). Truncated dystrophins reduce muscle stiffness in the extensor digitorum longus muscle of mdx mice. J. Appl. Physiol. 114, 482-489.
118. Hakim, C. H., Grange, R. W. and Duan, D. (2011). The passive mechanical properties of the extensor digitorum longus muscle are compromised in 2- to 20-mo-old mdx mice. J. Appl. Physiol. 110, 1656-1663.
119. Hakim, C. H., Yue, Y., Shin, J. H., Williams, R. R., Zhang, K., Smith, B. F. and Duan, D. (2014). Systemic gene transfer reveals distinctive muscle transduction profile of tyrosine mutant AAV-1, -6, and -9 in neonatal dogs. Mol Ther Methods Clin Dev 1, 14002.
120. Han, R., Rader, E. P., Levy, J. R., Bansal, D. and Campbell, K. P. (2011). Dystrophin deficiency exacerbates skeletal muscle pathology in dysferlin-null mice. Skelet Muscle 1, 35.
121. Harper, S. Q. (2013). Molecular dissection of dystrophin identifies the docking site for nNOS. Proc. Natl. Acad. Sci. USA 110, 387-388.
122. Harper, S. Q., Hauser, M. A., DelloRusso, C., Duan, D., Crawford, R. W., Phelps, S. F., Harper, H. A., Robinson, A. S., Engelhardt, J. F., Brooks, S. V. et al. (2002). Modular flexibility of dystrophin: implications for gene therapy of Duchenne muscular dystrophy. Nat. Med. 8, 253-261.
123. Hattori, N., Kaido, M., Nishigaki, T., Inui, K., Fujimura, H., Nishimura, T., Naka, T. and Hazama, T. (1999). Undetectable dystrophin can still result in a relatively benign phenotype of dystrophinopathy. Neuromuscul. Disord. 9, 220-226.
124. Hedlund, M., Tangvoranuntakul, P., Takematsu, H., Long, J. M., Housley, G. D., Kozutsumi, Y., Suzuki, A., Wynshaw-Boris, A., Ryan, A. F., Gallo, R. L. et al. (2007). N-glycolylneuraminic acid deficiency in mice: implications for human biology and evolution. Mol. Cell. Biol. 27, 4340-4346.
125. Heller, K. N., Montgomery, C. L., Janssen, P. M., Clark, K. R., Mendell, J. R. and Rodino-Klapac, L. R. (2013). AAV-mediated overexpression of human α7 integrin leads to histological and functional improvement in dystrophic mice. Mol. Ther. 21, 520-525.
126. Henricson, E. K., Abresch, R. T., Cnaan, A., Hu, F., Duong, T., Arrieta, A., Han, J., Escolar, D. M., Florence, J. M., Clemens, P. R. et al.; CINRG Investigators (2013). The cooperative international neuromuscular research group Duchenne natural history study: glucocorticoid treatment preserves clinically meaningful functional milestones and reduces rate of disease progression as measured by manual muscle testing and other commonly used clinical trial outcome measures. Muscle Nerve 48, 55-67.
127. Hoffman, E. P. and Gorospe, J. R. M. (1991). The animal models of Duchenne muscular dystrophy: windows on the pathophsiological consequences of dystrophin deficiency. Curr. Top. Membr. 38, 113-154.
128. Hoffman, E. P. and Kunkel, L. M. (1989). Dystrophin abnormalities in Duchenne/Becker muscular dystrophy. Neuron 2, 1019-1029.
129. Hoffman, E. P. and McNally, E. M. (2014). Exon-skipping therapy: a roadblock, detour, or bump in the road? Sci. Transl. Med. 6, 230fs14.
130. Hoffman, E. P., Brown, R. H., Jr and Kunkel, L. M. (1987). Dystrophin: the protein product of the Duchenne muscular dystrophy locus. Cell 51, 919-928.
131. Hoffman, E. P., Kunkel, L. M., Angelini, C., Clarke, A., Johnson, M. and Harris, J. B. (1989). Improved diagnosis of Becker muscular dystrophy by dystrophin testing. Neurology 39, 1011-1017.
132. Hollinger, K., Yang, C. X., Montz, R. E., Nonneman, D., Ross, J. W. and Selsby, J. T. (2014). Dystrophin insufficiency causes selective muscle histopathology and loss of dystrophin-glycoprotein complex assembly in pig skeletal muscle. FASEB J. 28, 1600-1609.
133. Hosur, V., Kavirayani, A., Riefler, J., Carney, L. M., Lyons, B., Gott, B., Cox, G. A. and Shultz, L. D. (2012). Dystrophin and dysferlin double mutant mice: a novel model for rhabdomyosarcoma. Cancer Genet 205, 232-241.
134. Howell, J. M., Lochmüller, H., O'Hara, A., Fletcher, S., Kakulas, B. A., Massie, B., Nalbantoglu, J. and Karpati, G. (1998). High-level dystrophin expression after adenovirus-mediated dystrophin minigene transfer to skeletal muscle of dystrophic dogs: prolongation of expression with immunosuppression. Hum. Gene Ther. 9, 629-634.
135. Huang, X., Poy, F., Zhang, R., Joachimiak, A., Sudol, M. and Eck, M. J. (2000). Structure of a WW domain containing fragment of dystrophin in complex with beta-dystroglycan. Nat. Struct. Biol. 7, 634-638.
136. Im, W. B., Phelps, S. F., Copen, E. H., Adams, E. G., Slightom, J. L. and Chamberlain, J. S. (1996). Differential expression of dystrophin isoforms in strains of mdx mice with different mutations. Hum. Mol. Genet. 5, 1149-1153.
137. Innes, J. R. (1951). Myopathies in animals; a record of some cases including progressive muscular dystrophy (pseudo-hypertrophic) (dog), "weisses Fleisch"(lamb), neuropathic muscular atrophy (sheep) and lymphocytic/histiocytic myositis, neuritis, radiculitis (dog). Br. Vet. J. 107, 131-143.
138. Ishizaki, M., Maeda, Y., Kawano, R., Suga, T., Uchida, Y., Uchino, K., Yamashita, S., Kimura, E. and Uchino, M. (2011). Rescue from respiratory dysfunction by transduction of full-length dystrophin to diaphragm via the peritoneal cavity in utrophin/dystrophin double knockout mice. Mol. Ther. 19, 1230-1235.
139. Jearawiriyapaisarn, N., Moulton, H. M., Buckley, B., Roberts, J., Sazani, P., Fucharoen, S., Iversen, P. L. and Kole, R. (2008). Sustained dystrophin expression induced by peptide-conjugated morpholino oligomers in the muscles of mdx mice. Mol. Ther. 16, 1624-1629.
140. Judge, L. M., Haraguchiln, M. and Chamberlain, J. S. (2006). Dissecting the signaling and mechanical functions of the dystrophin-glycoprotein complex. J. Cell Sci. 119, 1537-1546.
141. Judge, L. M., Arnett, A. L., Banks, G. B. and Chamberlain, J. S. (2011). Expression of the dystrophin isoform Dp116 preserves functional muscle mass and extends lifespan without preventing dystrophy in severely dystrophic mice. Hum. Mol. Genet. 20, 4978-4990.
142. Kawano, R., Ishizaki, M., Maeda, Y., Uchida, Y., Kimura, E. and Uchino, M. (2008). Transduction of full-length dystrophin to multiple skeletal muscles improves motor performance and life span in utrophin/dystrophin double knockout mice. Mol. Ther. 16, 825-831.
143. Kayali, R., Bury, F., Ballard, M. and Bertoni, C. (2010). Site-directed gene repair of the dystrophin gene mediated by PNA-ssODNs. Hum. Mol. Genet. 19, 3266-3281.
144. Kinali, M., Arechavala-Gomeza, V., Feng, L., Cirak, S., Hunt, D., Adkin, C., Guglieri, M., Ashton, E., Abbs, S., Nihoyannopoulos, P. et al. (2009). Local restoration of dystrophin expression with the morpholino oligomer AVI-4658 in Duchenne muscular dystrophy: a single-blind, placebo-controlled, dose-escalation, proof-of-concept study. Lancet Neurol. 8, 918-928.
145. Klymiuk, N., Blutke, A., Graf, A., Krause, S., Burkhardt, K., Wuensch, A., Krebs, S., Kessler, B., Zakhartchenko, V., Kurome, M. et al. (2013). Dystrophin-deficient pigs provide new insights into the hierarchy of physiological derangements of dystrophic muscle. Hum. Mol. Genet. 22, 4368-4382.
146. Kochanek, S., Clemens, P. R., Mitani, K., Chen, H. H., Chan, S. and Caskey, C. T. (1996). A new adenoviral vector: Replacement of all viral coding sequences with 28 kb of DNA independently expressing both full-length dystrophin and beta-galactosidase. Proc. Natl. Acad. Sci. USA 93, 5731-5736.
147. Koenig, M., Hoffman, E. P., Bertelson, C. J., Monaco, A. P., Feener, C. and Kunkel, L. M. (1987). Complete cloning of the Duchenne muscular dystrophy (DMD) cDNA and preliminary genomic organization of the DMD gene in normal and affected individuals. Cell 50, 509-517.
148. Konieczny, P., Swiderski, K. and Chamberlain, J. S. (2013). Gene and cell-mediated therapies for muscular dystrophy. Muscle Nerve 47, 649-663.
149. Koo, T. and Wood, M. J. (2013). Clinical trials using antisense oligonucleotides in Duchenne muscular dystrophy. Hum. Gene Ther. 24, 479-488.
150. Koo, T., Malerba, A., Athanasopoulos, T., Trollet, C., Boldrin, L., Ferry, A., Popplewell, L., Foster, H., Foster, K. and Dickson, G. (2011a). Delivery of AAV2/9-microdystrophin genes incorporating helix 1 of the coiled-coil motif in the C-terminal domain of dystrophin improves muscle pathology and restores the level of α1-syntrophin and α-dystrobrevin in skeletal muscles of mdx mice. Hum. Gene Ther. 522, 1379-1388.
151. Koo, T., Okada, T., Athanasopoulos, T., Foster, H., Takeda, S. and Dickson, G. (2011b). Long-term functional adeno-associated virus-microdystrophin expression in the dystrophic CXMDj dog. J. Gene Med. 13, 497-506.
152. Koo, T., Popplewell, L., Athanasopoulos, T. and Dickson, G. (2014). Triple transsplicing adeno-associated virus vectors capable of transferring the coding sequence for full-length dystrophin protein into dystrophic mice. Hum. Gene Ther. 25, 98-108.
153. Kornegay, J. N., Tuler, S. M., Miller, D. M. and Levesque, D. C. (1988). Muscular dystrophy in a litter of golden retriever dogs. Muscle Nerve 11, 1056-1064.
154. Kornegay, J. N., Li, J., Bogan, J. R., Bogan, D. J., Chen, C., Zheng, H., Wang, B., Qiao, C., Howard, J. F., Jr and Xiao, X. (2010). Widespread muscle expression of an AAV9 human mini-dystrophin vector after intravenous injection in neonatal dystrophin-deficient dogs. Mol. Ther. 18, 1501-1508.
155. Kornegay, J. N., Bogan, J. R., Bogan, D. J., Childers, M. K., Li, J., Nghiem, P., Detwiler, D. A., Larsen, C. A., Grange, R. W., Bhavaraju-Sanka, R. K. et al. (2012). Canine models of Duchenne muscular dystrophy and their use in therapeutic strategies. Mamm. Genome 23, 85-108.
156. Krivov, L. I., Stenina, M. A., Yarygin, V. N., Polyakov, A. V., Savchuk, V. I., Obrubov, S. A. and Komarova, N. V. (2009). A new genetic variant of mdx mice: study of the phenotype. Bull. Exp. Biol. Med. 147, 625-629.
157. Kumar-Singh, R. and Chamberlain, J. S. (1996). Encapsidated adenovirus minichromosomes allow delivery and expression of a 14 kb dystrophin cDNA to muscle cells. Hum. Mol. Genet. 5, 913-921.
158. Kunkel, L. M. (2005). 2004 William Allan award address. cloning of the DMD gene. Am. J. Hum. Genet. 76, 205-214.
159. Kunkel, L. M., Bachrach, E., Bennett, R. R., Guyon, J. and Steffen, L. (2006). Diagnosis and cell-based therapy for Duchenne muscular dystrophy in humans, mice, and zebrafish. J. Hum. Genet. 51, 397-406.
160. Lai, Y. and Duan, D. (2012). Progress in gene therapy of dystrophic heart disease. Gene Ther. 19, 678-685.
161. Lai, Y., Yue, Y., Liu, M., Ghosh, A., Engelhardt, J. F., Chamberlain, J. S. and Duan, D. (2005). Efficient in vivo gene expression by trans-splicing adeno-associated viral vectors. Nat. Biotechnol. 23, 1435-1439.
162. Lai, Y., Thomas, G. D., Yue, Y., Yang, H. T., Li, D., Long, C., Judge, L., Bostick, B., Chamberlain, J. S., Terjung, R. L. et al. (2009). Dystrophins carrying spectrin-like repeats 16 and 17 anchor nNOS to the sarcolemma and enhance exercise performance in a mouse model of muscular dystrophy. J. Clin. Invest. 119, 624-635.
163. Lai, Y., Zhao, J., Yue, Y. and Duan, D. (2013). α2 and α3 helices of dystrophin R16 and R17 frame a microdomain in the α1 helix of dystrophin R17 for neuronal NOS binding. Proc. Natl. Acad. Sci. USA 110, 525-530.
164. Lai, Y., Zhao, J., Yue, Y., Wasala, N. B. and Duan, D. (2014). Partial restoration of cardiac function with ΔPDZ nNOS in aged mdx model of Duchenne cardiomyopathy. Hum. Mol. Genet. 23, 3189-3199.
165. Lanfossi, M., Cozzi, F., Bugini, D., Colombo, S., Scarpa, P., Morandi, L., Galbiati, S., Cornelio, F., Pozza, O. and Mora, M. (1999). Development of muscle pathology in canine X-linked muscular dystrophy. I. Delayed postnatal maturation of affected and normal muscle as revealed by myosin isoform analysis and utrophin expression. Acta Neuropathol. 97, 127-138.
166. Le Guiner, C., Montus, M., Servais, L., Cherel, Y., Francois, V., Thibaud, J. L., Wary, C., Matot, B., Larcher, T., Guigand, L. et al. (2014). Forelimb treatment in a large cohort of dystrophic dogs supports delivery of a recombinant AAV for exon skipping in Duchenne patients. Mol. Ther. 22, 1923-1935.
167. Lee, S. J. (2004). Regulation of muscle mass by myostatin. Annu. Rev. Cell Dev. Biol. 20, 61-86.
168. Lefaucheur, J. P., Pastoret, C. and Sebille, A. (1995). Phenotype of dystrophinopathy in old mdx mice. Anat. Rec. 242, 70-76.
169. Leibovitz, S., Meshorer, A., Fridman, Y., Wieneke, S., Jockusch, H., Yaffe, D. and Nudel, U. (2002). Exogenous Dp71 is a dominant negative competitor of dystrophin in skeletal muscle. Neuromuscul. Disord. 12, 836-844.
170. Li, D., Yue, Y. and Duan, D. (2008). Preservation of muscle force in Mdx3cv mice correlates with low-level expression of a near full-length dystrophin protein. Am. J. Pathol. 172, 1332-1341.
171. Li, D., Long, C., Yue, Y. and Duan, D. (2009). Sub-physiological sarcoglycan expression contributes to compensatory muscle protection in mdx mice. Hum. Mol. Genet. 18, 1209-1220.
172. Li, D., Yue, Y. and Duan, D. (2010). Marginal level dystrophin expression improves clinical outcome in a strain of dystrophin/utrophin double knockout mice. PLoS ONE 5, e15286.
173. Li, D., Yue, Y., Lai, Y., Hakim, C. H. and Duan, D. (2011). Nitrosative stress elicited by nNOSμ delocalization inhibits muscle force in dystrophin-null mice. J. Pathol. 223, 88-98.
174. Lidov, H. G. (1996). Dystrophin in the nervous system. Brain Pathol. 6, 63-77.
175. Liu, Q., Perez, C. F. and Wang, Y. (2006). Efficient site-specific integration of large transgenes by an enhanced herpes simplex virus/adeno-associated virus hybrid amplicon vector. J. Virol. 80, 1672-1679.
176. Lloyd, T. E. and Taylor, J. P. (2010). Flightless flies: Drosophila models of neuromuscular disease. Ann. N. Y. Acad. Sci. 1184, e1-e20.
177. Long, C., McAnally, J. R., Shelton, J. M., Mireault, A. A., Bassel-Duby, R. and Olson, E. N. (2014). Prevention of muscular dystrophy in mice by CRISPR/Cas9-mediated editing of germline DNA. Science 345, 1184-1188.
178. Lostal, W., Kodippili, K., Yue, Y. and Duan, D. (2014). Full-length dystrophin reconstitution with adeno-associated viral vectors. Hum. Gene Ther. 25, 552-562.
179. Lu, Q. L., Mann, C. J., Lou, F., Bou-Gharios, G., Morris, G. E., Xue, S. A., Fletcher, S., Partridge, T. A. and Wilton, S. D. (2003). Functional amounts of dystrophin produced by skipping the mutated exon in the mdx dystrophic mouse. Nat. Med. 9, 1009-1014.
180. Lu, Q. L., Rabinowitz, A., Chen, Y. C., Yokota, T., Yin, H., Alter, J., Jadoon, A., Bou-Gharios, G. and Partridge, T. (2005). Systemic delivery of antisense oligoribonucleotide restores dystrophin expression in body-wide skeletal muscles. Proc. Natl. Acad. Sci. USA 102, 198-203.
181. Lu, Q. L., Yokota, T., Takeda, S., Garcia, L., Muntoni, F. and Partridge, T. (2011). The status of exon skipping as a therapeutic approach to duchenne muscular dystrophy. Mol. Ther. 19, 9-15.
182. Lynch, G. S., Hinkle, R. T., Chamberlain, J. S., Brooks, S. V. and Faulkner, J. A. (2001). Force and power output of fast and slow skeletal muscles from mdx mice 6-28 months old. J. Physiol. 535, 591-600.
183. Magri, F., Govoni, A., D'Angelo, M. G., Del Bo, R., Ghezzi, S., Sandra, G., Turconi, A. C., Sciacco, M., Ciscato, P., Bordoni, A. et al. (2011). Genotype and phenotype characterization in a large dystrophinopathic cohort with extended follow-up. J. Neurol. 258, 1610-1623.
184. Mann, C. J., Honeyman, K., Cheng, A. J., Ly, T., Lloyd, F., Fletcher, S., Morgan, J. E., Partridge, T. A. and Wilton, S. D. (2001). Antisense-induced exon skipping and synthesis of dystrophin in the mdx mouse. Proc. Natl. Acad. Sci. USA 98, 42-47.
185. Marshall, J. L., Kwok, Y., McMorran, B. J., Baum, L. G. and Crosbie-Watson, R. H. (2013). The potential of sarcospan in adhesion complex replacement therapeutics for the treatment of muscular dystrophy. FEBS J. 280, 4210-4229.
186. myd: a new mouse model of neuromuscular diseases useful for studying physiopathological mechanisms and testing therapies. Dis. Model. Mech. 6, 1167-1174.
187. McCabe, E. R., Towbin, J., Chamberlain, J., Baumbach, L., Witkowski, J., van Ommen, G. J., Koenig, M., Kunkel, L. M. and Seltzer, W. K. (1989). Complementary DNA probes for the Duchenne muscular dystrophy locus demonstrate a previously undetectable deletion in a patient with dystrophic myopathy, glycerol kinase deficiency, and congenital adrenal hypoplasia. J. Clin. Invest. 83, 95-99.
188. McClorey, G., Moulton, H. M., Iversen, P. L., Fletcher, S. and Wilton, S. D. (2006). Antisense oligonucleotide-induced exon skipping restores dystrophin expression in vitro in a canine model of DMD. Gene Ther. 13, 1373-1381.
189. McCully, K., Giger, U., Argov, Z., Valentine, B., Cooper, B., Chance, B. and Bank, W. (1991). Canine X-linked muscular dystrophy studied with in vivo phosphorus magnetic resonance spectroscopy. Muscle Nerve 14, 1091-1098.
190. McDonald, C. M., Henricson, E. K., Han, J. J., Abresch, R. T., Nicorici, A., Atkinson, L., Elfring, G. L., Reha, A. and Miller, L. L. (2010). The 6-minute walk test in Duchenne/Becker muscular dystrophy: longitudinal observations. Muscle Nerve 42, 966-974.
191. McDonald, C. M., Henricson, E. K., Abresch, R. T., Florence, J. M., Eagle, M., Gappmaier, E., Glanzman, A. M., Spiegel, R., Barth, J., Elfring, G. et al.; PTC124-GD-007-DMD Study Group (2013a). The 6-minute walk test and other endpoints in Duchenne muscular dystrophy: longitudinal natural history observations over 48 weeks from a multicenter study. Muscle Nerve 48, 343-356.
192. McDonald, C. M., Henricson, E. K., Abresch, R. T., Han, J. J., Escolar, D. M., Florence, J. M., Duong, T., Arrieta, A., Clemens, P. R., Hoffman, E. P. et al.; Cinrg Investigators (2013b). The cooperative international neuromuscular research group Duchenne natural history study - a longitudinal investigation in the era of glucocorticoid therapy: design of protocol and the methods used. Muscle Nerve 48, 32-54.
193. McPherron, A. C., Lawler, A. M. and Lee, S. J. (1997). Regulation of skeletal muscle mass in mice by a new TGF-beta superfamily member. Nature 387, 83-90.
194. Megeney, L. A., Kablar, B., Garrett, K., Anderson, J. E. and Rudnicki, M. A. (1996). MyoD is required for myogenic stem cell function in adult skeletal muscle. Genes Dev. 10, 1173-1183.
195. Megeney, L. A., Kablar, B., Perry, R. L., Ying, C., May, L. and Rudnicki, M. A. (1999). Severe cardiomyopathy in mice lacking dystrophin and MyoD. Proc. Natl. Acad. Sci. USA 96, 220-225.
196. Mendell, J. R. and Lloyd-Puryear, M. (2013). Report of MDA muscle disease symposium on newborn screening for Duchenne muscular dystrophy. Muscle Nerve 48, 21-26.
197. Mendell, J. R., Rodino-Klapac, L., Sahenk, Z., Malik, V., Kaspar, B. K., Walker, C. M. and Clark, K. R. (2012). Gene therapy for muscular dystrophy: lessons learned and path forward. Neurosci. Lett. 527, 90-99.
198. Mendell, J. R., Rodino-Klapac, L. R., Sahenk, Z., Roush, K., Bird, L., Lowes, L. P., Alfano, L., Gomez, A. M., Lewis, S., Kota, J. et al.; Eteplirsen Study Group (2013). Eteplirsen for the treatment of Duchenne muscular dystrophy. Ann. Neurol. 74, 637-647.
199. Mendell, J. R., Sahenk, Z., Malik, V., Gomez, A. M., Flanigan, K. M., Lowes, L. P., Alfano, L. N., Berry, K., Meadows, E., Lewis, S. et al. (2015). A phase 1/2a follistatin gene therapy trial for Becker muscular dystrophy. Mol. Ther. 23, 192-201.
200. Mercuri, E. and Muntoni, F. (2013). Muscular dystrophy: new challenges and review of the current clinical trials. Curr. Opin. Pediatr. 25, 701-707.
201. Miranda, R., Sébrié, C., Degrouard, J., Gillet, B., Jaillard, D., Laroche, S. and Vaillend, C. (2009). Reorganization of inhibitory synapses and increased PSD length of perforated excitatory synapses in hippocampal area CA1 of dystrophin-deficient mdx mice. Cereb. Cortex 19, 876-888.
202. Miranda, R., Nudel, U., Laroche, S. and Vaillend, C. (2011). Altered presynaptic ultrastructure in excitatory hippocampal synapses of mice lacking dystrophins Dp427 or Dp71. Neurobiol. Dis. 43, 134-141.
203. Miyazato, L. G., Moraes, J. R., Beretta, D. C. and Kornegay, J. N. (2011). Muscular dystrophy in dogs: does the crossing of breeds influence disease phenotype? Vet. Pathol. 48, 655-662.
204. Moise, N. S., Valentine, B. A., Brown, C. A., Erb, H. N., Beck, K. A., Cooper, B. J. and Gilmour, R. F. (1991). Duchenne's cardiomyopathy in a canine model: electrocardiographic and echocardiographic studies. J. Am. Coll. Cardiol. 17, 812-820.
205. Moizard, M. P., Billard, C., Toutain, A., Berret, F., Marmin, N. and Moraine, C. (1998). Are Dp71 and Dp140 brain dystrophin isoforms related to cognitive impairment in Duchenne muscular dystrophy? Am. J. Med. Genet. 80, 32-41.
206. Moizard, M. P., Toutain, A., Fournier, D., Berret, F., Raynaud, M., Billard, C., Andres, C. and Moraine, C. (2000). Severe cognitive impairment in DMD: obvious clinical indication for Dp71 isoform point mutation screening. Eur. J. Hum. Genet. 8, 552-556.
207. Monaco, A. P., Neve, R. L., Colletti-Feener, C., Bertelson, C. J., Kurnit, D. M. and Kunkel, L. M. (1986). Isolation of candidate cDNAs for portions of the Duchenne muscular dystrophy gene. Nature 323, 646-650.
208. Monaco, A. P., Bertelson, C. J., Liechti-Gallati, S., Moser, H. and Kunkel, L. M. (1988). An explanation for the phenotypic differences between patients bearing partial deletions of the DMD locus. Genomics 2, 90-95.
209. Morrison, J., Lu, Q. L., Pastoret, C., Partridge, T. and Bou-Gharios, G. (2000). T-cell-dependent fibrosis in the mdx dystrophic mouse. Lab. Invest. 80, 881-891.
210. Mourkioti, F., Kustan, J., Kraft, P., Day, J. W., Zhao, M. M., Kost-Alimova, M., Protopopov, A., DePinho, R. A., Bernstein, D., Meeker, A. K. et al. (2013). Role of telomere dysfunction in cardiac failure in Duchenne muscular dystrophy. Nat. Cell Biol. 15, 895-904.
211. Muntoni, F., Mateddu, A. and Serra, G. (1991). Passive avoidance behaviour deficit in the mdx mouse. Neuromuscul. Disord. 1, 121-123.
212. Nakamura, A., Yoshida, K., Fukushima, K., Ueda, H., Urasawa, N., Koyama, J., Yazaki, Y., Yazaki, M., Sakai, T., Haruta, S. et al. (2008). Follow-up of three patients with a large in-frame deletion of exons 45-55 in the Duchenne muscular dystrophy (DMD) gene. J. Clin. Neurosci. 15, 757-763.
213. Nakamura, A., Kobayashi, M., Kuraoka, M., Yuasa, K., Yugeta, N., Okada, T. and Takeda, S. (2013). Initial pulmonary respiration causes massive diaphragm damage and hyper-CKemia in Duchenne muscular dystrophy dog. Sci. Rep. 3, 2183.
214. Nakamura, K., Fujii, W., Tsuboi, M., Tanihata, J., Teramoto, N., Takeuchi, S., Naito, K., Yamanouchi, K. and Nishihara, M. (2014). Generation of muscular dystrophy model rats with a CRISPR/Cas system. Sci. Rep. 4, 5635.
215. Nardes, F., Araújo, A. P. and Ribeiro, M. G. (2012). Mental retardation in Duchenne muscular dystrophy. J. Pediatr. (Rio J.) 88, 6-16.
216. Neri, M., Torelli, S., Brown, S., Ugo, I., Sabatelli, P., Merlini, L., Spitali, P., Rimessi, P., Gualandi, F., Sewry, C. et al. (2007). Dystrophin levels as low as 30% are sufficient to avoid muscular dystrophy in the human. Neuromuscul. Disord. 17, 913-918.
217. Nguyen, F., Cherel, Y., Guigand, L., Goubault-Leroux, I. and Wyers, M. (2002). Muscle lesions associated with dystrophin deficiency in neonatal golden retriever puppies. J. Comp. Pathol. 126, 100-108.
218. Nicholson, L. V., Johnson, M. A., Bushby, K. M. and Gardner-Medwin, D. (1993a). Functional significance of dystrophin positive fibres in Duchenne muscular dystrophy. Arch. Dis. Child. 68, 632-636.
219. Nicholson, L. V., Johnson, M. A., Bushby, K. M., Gardner-Medwin, D., Curtis, A., Ginjaar, I. B., den Dunnen, J. T., Welch, J. L., Butler, T. J., Bakker, E. et al. (1993b). Integrated study of 100 patients with Xp21 linked muscular dystrophy using clinical, genetic, immunochemical, and histopathological data. Part 1. Trends across the clinical groups. J. Med. Genet. 30, 728-736.
220. Nishimura, D., Sakai, H., Sato, T., Sato, F., Nishimura, S., Toyama-Sorimachi, N., Bartsch, J. W. and Sehara-Fujisawa, A. (2015). Roles of ADAM8 in elimination of injured muscle fibers prior to skeletal muscle regeneration. Mech. Dev. 135, 58-67.
221. Nitahara-Kasahara, Y., Hayashita-Kinoh, H., Chiyo, T., Nishiyama, A., Okada, H., Takeda, S. and Okada, T. (2014). Dystrophic mdx mice develop severe cardiac and respiratory dysfunction following genetic ablation of the anti-inflammatory cytokine IL-10. Hum. Mol. Genet. 23, 3990-4000.
222. Nonneman, D. J., Brown-Brandl, T., Jones, S. A., Wiedmann, R. T. and Rohrer, G. A. (2012). A defect in dystrophin causes a novel porcine stress syndrome. BMC Genomics 13, 233.
223. Odom, G. L., Gregorevic, P., Allen, J. M., Finn, E. and Chamberlain, J. S. (2008). Microutrophin delivery through rAAV6 increases lifespan and improves muscle function in dystrophic dystrophin/utrophin-deficient mice. Mol. Ther. 16, 1539-1545.
224. Odom, G. L., Gregorevic, P., Allen, J. M. and Chamberlain, J. S. (2011). Gene therapy of mdx mice with large truncated dystrophins generated by recombination using rAAV6. Mol. Ther. 19, 36-45.
225. Ohshima, S., Shin, J. H., Yuasa, K., Nishiyama, A., Kira, J., Okada, T. and Takeda, S. (2009). Transduction efficiency and immune response associated with the administration of AAV8 vector into dog skeletal muscle. Mol. Ther. 17, 73-80.
226. Opar, A. (2012). Exon-skipping drug pulls ahead in muscular dystrophy field. Nat. Med. 18, 1314.
227. Ousterout, D. G., Perez-Pinera, P., Thakore, P. I., Kabadi, A. M., Brown, M. T., Qin, X., Fedrigo, O., Mouly, V., Tremblay, J. P. and Gersbach, C. A. (2013). Reading frame correction by targeted genome editing restores dystrophin expression in cells from Duchenne muscular dystrophy patients. Mol. Ther. 21, 1718-1726.
228. Ousterout, D. G., Kabadi, A. M., Thakore, P. I., Perez-Pinera, P., Brown, M. T., Majoros, W. H., Reddy, T. E. and Gersbach, C. A. (2014). Correction of dystrophin expression in cells from Duchenne Muscular Dystrophy patients through genomic excision of Exon 51 by zinc finger nucleases. Mol. Ther. [Epub ahead of print] doi: 10.1038/mt.2014.234.
229. Pacak, C. A., Mah, C. S., Thattaliyath, B. D., Conlon, T. J., Lewis, M. A., Cloutier, D. E., Zolotukhin, I., Tarantal, A. F. and Byrne, B. J. (2006). Recombinant adeno-associated virus serotype 9 leads to preferential cardiac transduction in vivo. Circ. Res. 99, e3-e9.
230. Pan, X., Yue, Y., Zhang, K., Lostal, W., Shin, J. H. and Duan, D. (2013). Long-term robust myocardial transduction of the dog heart from a peripheral vein by adeno-associated virus serotype-8. Hum. Gene Ther. 24, 584-594.
231. Pane, M., Lombardo, M. E., Alfieri, P., D'Amico, A., Bianco, F., Vasco, G., Piccini, G., Mallardi, M., Romeo, D. M., Ricotti, V. et al. (2012). Attention deficit hyperactivity disorder and cognitive function in Duchenne muscular dystrophy: phenotype-genotype correlation. J. Pediatr. 161, 705-709 e1.
232. Parames, S. F., Coletta-Yudice, E. D., Nogueira, F. M., Nering de Sousa, M. B., Hayashi, M. A., Lima-Landman, M. T., Lapa, A. J. and Souccar, C. (2014). Altered acetylcholine release in the hippocampus of dystrophin-deficient mice. Neuroscience 269, 173-183.
233. Partridge, T. and Lu, Q. L. (2008). The enigma of the 'dystrophin revertant' muscle fibre. In Recent Advances in Skeletal Muscle Differentiation (ed. T. Kunihiro and S. Takeda), pp. 93-107. Kerala: Research Signpost.
234. Pastoret, C. and Sebille, A. (1995). Mdx mice show progressive weakness and muscle deterioration with age. J. Neurol. Sci. 129, 97-105.
235. Patria, S. Y., Alimsardjono, H., Nishio, H., Takeshima, Y., Nakamura, H. and Matsuo, M. (1996). A case of Becker muscular dystrophy resulting from the skipping of four contiguous exons (71-74) of the dystrophin gene during mRNA maturation. Proc. Assoc. Am. Physicians 108, 308-314.
236. Perronnet, C., Chagneau, C., Le Blanc, P., Samson-Desvignes, N., Mornet, D., Laroche, S., De La Porte, S. and Vaillend, C. (2012). Upregulation of brain utrophin does not rescue behavioral alterations in dystrophin-deficient mice. Hum. Mol. Genet. 21, 2263-2276.
237. Phelps, S. F., Hauser, M. A., Cole, N. M., Rafael, J. A., Hinkle, R. T., Faulkner, J. A. and Chamberlain, J. S. (1995). Expression of full-length and truncated dystrophin mini-genes in transgenic mdx mice. Hum. Mol. Genet. 4, 1251-1258.
238. Poussin, G., Mathis, C., Alexopoulos, L. G., Messinis, D. E., Dulize, R. H. J., Belcastro, V., Melas, I. N., Sakellaropoulos, T., Rhrissorrakrai, K., Bilal, E. et al. (2014). The species translation challenge - a systems biology perspective on human and rat bronchial epithelial cells. Sci. Data 1, 140009.
239. Rafael, J. A., Tinsley, J. M., Potter, A. C., Deconinck, A. E. and Davies, K. E. (1998). Skeletal muscle-specific expression of a utrophin transgene rescues utrophin-dystrophin deficient mice. Nat. Genet. 19, 79-82.
240. Rafael-Fortney, J. A., Chimanji, N. S., Schill, K. E., Martin, C. D., Murray, J. D., Ganguly, R., Stangland, J. E., Tran, T., Xu, Y., Canan, B. D. et al. (2011). Early treatment with lisinopril and spironolactone preserves cardiac and skeletal muscle in Duchenne muscular dystrophy mice. Circulation 124, 582-588.
241. Ragot, T., Vincent, N., Chafey, P., Vigne, E., Gilgenkrantz, H., Couton, D., Cartaud, J., Briand, P., Kaplan, J. C., Perricaudet, M. et al. (1993). Efficient adenovirus-mediated transfer of a human minidystrophin gene to skeletal muscle of mdx mice. Nature 361, 647-650.
242. Rando, T. A., Disatnik, M. H. and Zhou, L. Z. (2000). Rescue of dystrophin expression in mdx mouse muscle by RNA/DNA oligonucleotides. Proc. Natl. Acad. Sci. USA 97, 5363-5368.
243. Ricotti, V., Roberts, R. G. and Muntoni, F. (2011). Dystrophin and the brain. Dev. Med. Child Neurol. 53, 12.
244. Rodino-Klapac, L. R., Haidet, A. M., Kota, J., Handy, C., Kaspar, B. K. and Mendell, J. R. (2009). Inhibition of myostatin with emphasis on follistatin as a therapy for muscle disease. Muscle Nerve 39, 283-296.
245. Rooney, J. E., Welser, J. V., Dechert, M. A., Flintoff-Dye, N. L., Kaufman, S. J. and Burkin, D. J. (2006). Severe muscular dystrophy in mice that lack dystrophin and alpha7 integrin. J. Cell Sci. 119, 2185-2195.
246. Rousseau, J., Chapdelaine, P., Boisvert, S., Almeida, L. P., Corbeil, J., Montpetit, A. and Tremblay, J. P. (2011). Endonucleases: tools to correct the dystrophin gene. J. Gene Med. 13, 522-537.
247. Rutledge, E. A., Halbert, C. L. and Russell, D. W. (1998). Infectious clones and vectors derived from adeno-associated virus (AAV) serotypes other than AAV type 2. J. Virol. 72, 309-319.
248. Sacco, A., Mourkioti, F., Tran, R., Choi, J., Llewellyn, M., Kraft, P., Shkreli, M., Delp, S., Pomerantz, J. H., Artandi, S. E. et al. (2010). Short telomeres and stem cell exhaustion model Duchenne muscular dystrophy in mdx/mTR mice. Cell 143, 1059-1071.
249. Sampaolesi, M., Blot, S., D'Antona, G., Granger, N., Tonlorenzi, R., Innocenzi, A., Mognol, P., Thibaud, J. L., Galvez, B. G., Barthélémy, I. et al. (2006). Mesoangioblast stem cells ameliorate muscle function in dystrophic dogs. Nature 444, 574-579.
250. Sarig, R., Mezger-Lallemand, V., Gitelman, I., Davis, C., Fuchs, O., Yaffe, D. and Nudel, U. (1999). Targeted inactivation of Dp71, the major non-muscle product of the DMD gene: differential activity of the Dp71 promoter during development. Hum. Mol. Genet. 8, 1-10.
251. Schatzberg, S. J., Olby, N. J., Breen, M., Anderson, L. V., Langford, C. F., Dickens, H. F., Wilton, S. D., Zeiss, C. J., Binns, M. M., Kornegay, J. N. et al. (1999). Molecular analysis of a spontaneous dystrophin 'knockout' dog. Neuromuscul. Disord. 9, 289-295.
252. Schinkel, S., Bauer, R., Bekeredjian, R., Stucka, R., Rutschow, D., Lochmüller, H., Kleinschmidt, J. A., Katus, H. A. and Müller, O. J. (2012). Long-term preservation of cardiac structure and function after adeno-associated virus serotype 9-mediated microdystrophin gene transfer in mdx mice. Hum. Gene Ther. 23, 566-575.
253. Schmidt, W. M., Uddin, M. H., Dysek, S., Moser-Thier, K., Pirker, C., Höger, H., Ambros, I. M., Ambros, P. F., Berger, W. and Bittner, R. E. (2011). DNA damage, somatic aneuploidy, and malignant sarcoma susceptibility in muscular dystrophies. PLoS Genet. 7, e1002042.
254. Sekiguchi, M., Zushida, K., Yoshida, M., Maekawa, M., Kamichi, S., Yoshida, M., Sahara, Y., Yuasa, S., Takeda, S. and Wada, K. (2009). A deficit of brain dystrophin impairs specific amygdala GABAergic transmission and enhances defensive behaviour in mice. Brain 132, 124-135.
255. Selsby, J. T., Morine, K. J., Pendrak, K., Barton, E. R. and Sweeney, H. L. (2012). Rescue of dystrophic skeletal muscle by PGC-1α involves a fast to slow fiber type shift in the mdx mouse. PLoS ONE 7, e30063.
256. Sharp, N. J., Kornegay, J. N., Van Camp, S. D., Herbstreith, M. H., Secore, S. L., Kettle, S., Hung, W. Y., Constantinou, C. D., Dykstra, M. J., Roses, A. D. et al. (1992). An error in dystrophin mRNA processing in golden retriever muscular dystrophy, an animal homologue of Duchenne muscular dystrophy. Genomics 13, 115-121.
257. Shelton, G. D. and Engvall, E. (2005). Canine and feline models of human inherited muscle diseases. Neuromuscul. Disord. 15, 127-138.
258. Shimatsu, Y., Katagiri, K., Furuta, T., Nakura, M., Tanioka, Y., Yuasa, K., Tomohiro, M., Kornegay, J. N., Nonaka, I. and Takeda, S. (2003). Canine X-linked muscular dystrophy in Japan (CXMDJ). Exp. Anim. 52, 93-97.
259. Shimatsu, Y., Yoshimura, M., Yuasa, K., Urasawa, N., Tomohiro, M., Nakura, M., Tanigawa, M., Nakamura, A. and Takeda, S. (2005). Major clinical and histopathological characteristics of canine X-linked muscular dystrophy in Japan, CXMDJ. Acta Myol. 24, 145-154.
260. Shin, J.-H., Bostick, B., Yue, Y. and Duan, D. (2010). Duchenne cardiomyopathy gene therapy. In Muscle Gene Therapy (ed. D. Duan), pp. 141-162. New York, NY: Springer Science + Business Media, LLC.
261. Shin, J. H., Bostick, B., Yue, Y., Hajjar, R. and Duan, D. (2011a). SERCA2a gene transfer improves electrocardiographic performance in aged mdx mice. J. Transl. Med. 9, 132.
262. Shin, J. H., Nitahara-Kasahara, Y., Hayashita-Kinoh, H., Ohshima-Hosoyama, S., Kinoshita, K., Chiyo, T., Okada, H., Okada, T. and Takeda, S. (2011b). Improvement of cardiac fibrosis in dystrophic mice by rAAV9-mediated microdystrophin transduction. Gene Ther. 18, 910-919.
263. Shin, J. H., Yue, Y., Smith, B. and Duan, D. (2012a). Humoral immunity to AAV-6, 8, and 9 in normal and dystrophic dogs. Hum. Gene Ther. 23, 287-294.
264. Shin, J. H., Yue, Y., Srivastava, A., Smith, B., Lai, Y. and Duan, D. (2012b). A simplified immune suppression scheme leads to persistent micro-dystrophin expression in Duchenne muscular dystrophy dogs. Hum. Gene Ther. 23, 202-209.
265. Shin, J. H., Greer, B., Hakim, C. H., Zhou, Z., Chung, Y. C., Duan, Y., He, Z. and Duan, D. (2013a). Quantitative phenotyping of Duchenne muscular dystrophy dogs by comprehensive gait analysis and overnight activity monitoring. PLoS ONE 8, e59875.
266. Shin, J. H., Pan, X., Hakim, C. H., Yang, H. T., Yue, Y., Zhang, K., Terjung, R. L. and Duan, D. (2013b). Microdystrophin ameliorates muscular dystrophy in the canine model of duchenne muscular dystrophy. Mol. Ther. 21, 750-757.
267. Sicinski, P., Geng, Y., Ryder-Cook, A. S., Barnard, E. A., Darlison, M. G. and Barnard, P. J. (1989). The molecular basis of muscular dystrophy in the mdx mouse: a point mutation. Science 244, 1578-1580.
268. Sifringer, M., Uhlenberg, B., Lammel, S., Hanke, R., Neumann, B., von Moers, A., Koch, I. and Speer, A. (2004). Identification of transcripts from a subtraction library which might be responsible for the mild phenotype in an intrafamilially variable course of Duchenne muscular dystrophy. Hum. Genet. 114, 149-156.
269. Smith, K. (2011). Feline muscular dystrophy: parallels between cats and people. Vet. Rec. 168, 507-508.
270. Smith, B. F., Kornegay, J. N. and Duan, D. (2007). Independent canine models of Duchenne muscular dystrophy due to intronic insertions of repetitive DNA. Mol. Ther. 15, S51.
271. Smith, B. F., Yue, Y., Woods, P. R., Kornegay, J. N., Shin, J. H., Williams, R. R. and Duan, D. (2011). An intronic LINE-1 element insertion in the dystrophin gene aborts dystrophin expression and results in Duchenne-like muscular dystrophy in the corgi breed. Lab. Invest. 91, 216-231.
272. Snow, W. M., Anderson, J. E. and Jakobson, L. S. (2013). Neuropsychological and neurobehavioral functioning in Duchenne muscular dystrophy: a review. Neurosci. Biobehav. Rev. 37, 743-752.
273. Spitali, P. and Aartsma-Rus, A. (2012). Splice modulating therapies for human disease. Cell 148, 1085-1088.
274. Spurney, C., Shimizu, R., Morgenroth, L. P., Kolski, H., Gordish-Dressman, H., Clemens, P. R.; CINRG Investigators (2014). Cooperative International Neuromuscular Research Group Duchenne Natural History Study demonstrates insufficient diagnosis and treatment of cardiomyopathy in Duchenne muscular dystrophy. Muscle Nerve 50, 250-256.
275. Stedman, H. H., Sweeney, H. L., Shrager, J. B., Maguire, H. C., Panettieri, R. A., Petrof, B., Narusawa, M., Leferovich, J. M., Sladky, J. T. and Kelly, A. M. (1991). The mdx mouse diaphragm reproduces the degenerative changes of Duchenne muscular dystrophy. Nature 352, 536-539.
276. Stenina, M. A., Krivov, L. I., Voevodin, D. A. and Yarygin, V. N. (2013). Phenotypic differences between mdx black mice and mdx albino mice. Comparison of cytokine levels in the blood. Bull. Exp. Biol. Med. 155, 376-379.
277. Stinckens, A., Georges, M. and Buys, N. (2011). Mutations in the myostatin gene leading to hypermuscularity in mammals: indications for a similar mechanism in fish? Anim. Genet. 42, 229-234.
278. Taylor, P. J., Betts, G. A., Maroulis, S., Gilissen, C., Pedersen, R. L., Mowat, D. R., Johnston, H. M. and Buckley, M. F. (2010). Dystrophin gene mutation location and the risk of cognitive impairment in Duchenne muscular dystrophy. PLoS ONE 5, e8803.
279. Thomas, G. D. (2013). Functional muscle ischemia in Duchenne and Becker muscular dystrophy. Front. Physiol. 4, 381.
280. Tinsley, J. M., Potter, A. C., Phelps, S. R., Fisher, R., Trickett, J. I. and Davies, K. E. (1996). Amelioration of the dystrophic phenotype of mdx mice using a truncated utrophin transgene. Nature 384, 349-353.
281. Tinsley, J., Deconinck, N., Fisher, R., Kahn, D., Phelps, S., Gillis, J. M. and Davies, K. (1998). Expression of full-length utrophin prevents muscular dystrophy in mdx mice. Nat. Med. 4, 1441-1444.
282. Townsend, D., Blankinship, M. J., Allen, J. M., Gregorevic, P., Chamberlain, J. S. and Metzger, J. M. (2007). Systemic administration of micro-dystrophin restores cardiac geometry and prevents dobutamine-induced cardiac pump failure. Mol. Ther. 15, 1086-1092.
283. Townsend, D., Yasuda, S., Li, S., Chamberlain, J. S. and Metzger, J. M. (2008). Emergent dilated cardiomyopathy caused by targeted repair of dystrophic skeletal muscle. Mol. Ther. 16, 832-835.
284. Tozawa, T., Itoh, K., Yaoi, T., Tando, S., Umekage, M., Dai, H., Hosoi, H. and Fushiki, S. (2012). The shortest isoform of dystrophin (Dp40) interacts with a group of presynaptic proteins to form a presumptive novel complex in the mouse brain. Mol. Neurobiol. 45, 287-297.
285. Tuffery-Giraud, S., Béroud, C., Leturcq, F., Yaou, R. B., Hamroun, D., Michel-Calemard, L., Moizard, M. P., Bernard, R., Cossée, M., Boisseau, P. et al. (2009). Genotype-phenotype analysis in 2,405 patients with a dystrophinopathy using the UMD-DMD database: a model of nationwide knowledgebase. Hum. Mutat. 30, 934-945.
286. Vaillend, C. and Ungerer, A. (1999). Behavioral characterization of mdx3cv mice deficient in C-terminal dystrophins. Neuromuscul. Disord. 9, 296-304.
287. Vaillend, C., Rendon, A., Misslin, R. and Ungerer, A. (1995). Influence of dystrophingene mutation on mdx mouse behavior. I. Retention deficits at long delays in spontaneous alternation and bar-pressing tasks. Behav. Genet. 25, 569-579.
288. Vaillend, C., Billard, J. M., Claudepierre, T., Rendon, A., Dutar, P. and Ungerer, A. (1998). Spatial discrimination learning and CA1 hippocampal synaptic plasticity in mdx and mdx3cv mice lacking dystrophin gene products. Neuroscience 86, 53-66.
289. Vaillend, C., Ungerer, A. and Billard, J. M. (1999). Facilitated NMDA receptor-mediated synaptic plasticity in the hippocampal CA1 area of dystrophin-deficient mice. Synapse 33, 59-70.
290. Vaillend, C., Billard, J. M. and Laroche, S. (2004). Impaired long-term spatial and recognition memory and enhanced CA1 hippocampal LTP in the dystrophin-deficient Dmd(mdx) mouse. Neurobiol. Dis. 17, 10-20.
291. A-receptor clustering in the hippocampus of the mdx mouse. Mol. Ther. 18, 1683-1688.
292. Valentine, B. A. and Cooper, B. J. (1991). Canine X-linked muscular dystrophy: selective involvement of muscles in neonatal dogs. Neuromuscul. Disord. 1, 31-38.
293. Valentine, B. A., Cooper, B. J., Cummings, J. F. and deLahunta, A. (1986). Progressive muscular dystrophy in a golden retriever dog: light microscope and ultrastructural features at 4 and 8 months. Acta Neuropathol. 71, 301-310.
294. Valentine, B. A., Cooper, B. J., de Lahunta, A., O'Quinn, R. and Blue, J. T. (1988). Canine X-linked muscular dystrophy. An animal model of Duchenne muscular dystrophy: clinical studies. J. Neurol. Sci. 88, 69-81.
295. Valentine, B. A., Blue, J. T. and Cooper, B. J. (1989a). The effect of exercise on canine dystrophic muscle. Ann. Neurol. 26, 588.
296. Valentine, B. A., Cooper, B. J. and Gallagher, E. A. (1989b). Intracellular calcium in canine muscle biopsies. J. Comp. Pathol. 100, 223-230.
297. Valentine, B. A., Cummings, J. F. and Cooper, B. J. (1989c). Development of Duchenne-type cardiomyopathy. Morphologic studies in a canine model. Am. J. Pathol. 135, 671-678.
298. Valentine, B. A., Kornegay, J. N. and Cooper, B. J. (1989d). Clinical electromyographic studies of canine X-linked muscular dystrophy. Am. J. Vet. Res. 50, 2145-2147.
299. Valentine, B. A., Blue, J. T., Shelley, S. M. and Cooper, B. J. (1990a). Increased serum alanine aminotransferase activity associated with muscle necrosis in the dog. J. Vet. Intern. Med. 4, 140-143.
300. Valentine, B. A., Cooper, B. J., Cummings, J. F. and de Lahunta, A. (1990b). Canine X-linked muscular dystrophy: morphologic lesions. J. Neurol. Sci. 97, 1-23.
301. Valentine, B. A., Chandler, S. K., Cummings, J. F. and Cooper, B. J. (1991). In vitro characteristics of normal and dystrophic skeletal muscle from dogs. Am. J. Vet. Res. 52, 104-107.
302. Valentine, B. A., Winand, N. J., Pradhan, D., Moise, N. S., de Lahunta, A., Kornegay, J. N. and Cooper, B. J. (1992). Canine X-linked muscular dystrophy as an animal model of Duchenne muscular dystrophy: a review. Am. J. Med. Genet. 42, 352-356.
303. - mouse: a novel dystrophic and immunodeficient model to assess innovating therapeutic strategies for muscular dystrophies. Mol. Ther. 21, 1950-1957.
304. van Deutekom, J. C., Janson, A. A., Ginjaar, I. B., Frankhuizen, W. S., Aartsma-Rus, A., Bremmer-Bout, M., den Dunnen, J. T., Koop, K., van der Kooi, A. J., Goemans, N. M. et al. (2007). Local dystrophin restoration with antisense oligonucleotide PRO051. N. Engl. J. Med. 357, 2677-2686.
305. van Putten, M., Hulsker, M., Nadarajah, V. D., van Heiningen, S. H., van Huizen, E., van Iterson, M., Admiraal, P., Messemaker, T., den Dunnen, J. T., 't Hoen, P. A. et al. (2012a). The effects of low levels of dystrophin on mouse muscle function and pathology. PLoS ONE 7, e31937.
306. van Putten, M., Kumar, D., Hulsker, M., Hoogaars, W. M., Plomp, J. J., van Opstal, A., van Iterson, M., Admiraal, P., van Ommen, G. J., 't Hoen, P. A. et al. (2012b). Comparison of skeletal muscle pathology and motor function of dystrophin and utrophin deficient mouse strains. Neuromuscul. Disord. 22, 406-417.
307. van Putten, M., Hulsker, M., Young, C., Nadarajah, V. D., Heemskerk, H., van der Weerd, L., 't Hoen, P. A., van Ommen, G. J. and Aartsma-Rus, A. M. (2013). Low dystrophin levels increase survival and improve muscle pathology and function in dystrophin/utrophin double-knockout mice. FASEB J. 27, 2484-2495.
308. Varki, A. (2010). Colloquium paper: uniquely human evolution of sialic acid genetics and biology. Proc. Natl. Acad. Sci. USA 107 Suppl. 2, 8939-8946.
309. Verhaart, I. E. and Aartsma-Rus, A. (2012). Gene therapy for Duchenne muscular dystrophy. Curr. Opin. Neurol. 25, 588-596.
310. Vulin, A., Barthélémy, I., Goyenvalle, A., Thibaud, J. L., Beley, C., Griffith, G., Benchaouir, R., le Hir, M., Unterfinger, Y., Lorain, S. et al. (2012). Muscle function recovery in golden retriever muscular dystrophy after AAV1-U7 exon skipping. Mol. Ther. 20, 2120-2133.
311. Wagner, K. R., McPherron, A. C., Winik, N. and Lee, S. J. (2002). Loss of myostatin attenuates severity of muscular dystrophy in mdx mice. Ann. Neurol. 52, 832-836.
312. Wakefield, P. M., Tinsley, J. M., Wood, M. J., Gilbert, R., Karpati, G. and Davies, K. E. (2000). Prevention of the dystrophic phenotype in dystrophin/utrophin-deficient muscle following adenovirus-mediated transfer of a utrophin minigene. Gene Ther. 7, 201-204.
313. Wakefield, S. E., Dimberg, E. L., Moore, S. A. and Tseng, B. S. (2009). Dystrophinopathy presenting with arrhythmia in an asymptomatic 34-year-old man: a case report. J. Med. Case Rep. 3, 8625.
314. Walmsley, G. L., Arechavala-Gomeza, V., Fernandez-Fuente, M., Burke, M. M., Nagel, N., Holder, A., Stanley, R., Chandler, K., Marks, S. L., Muntoni, F. et al. (2010). A Duchenne muscular dystrophy gene hot spot mutation in dystrophin-deficient Cavalier King Charles spaniels is amenable to exon 51 skipping. PLoS ONE 5, e8647.
315. 41Dmd(mdx) deficient mouse model. PLoS ONE 6, e27500.
316. Wang, B., Li, J. and Xiao, X. (2000). Adeno-associated virus vector carrying human minidystrophin genes effectively ameliorates muscular dystrophy in mdx mouse model. Proc. Natl. Acad. Sci. USA 97, 13714-13719.
317. Wang, Z., Zhu, T., Qiao, C., Zhou, L., Wang, B., Zhang, J., Chen, C., Li, J. and Xiao, X. (2005). Adeno-associated virus serotype 8 efficiently delivers genes to muscle and heart. Nat. Biotechnol. 23, 321-328.
318. Wang, Z., Kuhr, C. S., Allen, J. M., Blankinship, M., Gregorevic, P., Chamberlain, J. S., Tapscott, S. J. and Storb, R. (2007). Sustained AAV-mediated dystrophin expression in a canine model of Duchenne muscular dystrophy with a brief course of immunosuppression. Mol. Ther. 15, 1160-1166.
319. Wang, Y., Marino-Enriquez, A., Bennett, R. R., Zhu, M., Shen, Y., Eilers, G., Lee, J. C., Henze, J., Fletcher, B. S., Gu, Z. et al. (2014). Dystrophin is a tumor suppressor in human cancers with myogenic programs. Nat. Genet. 46, 601-606.
320. Warner, L. E., DelloRusso, C., Crawford, R. W., Rybakova, I. N., Patel, J. R., Ervasti, J. M. and Chamberlain, J. S. (2002). Expression of Dp260 in muscle tethers the actin cytoskeleton to the dystrophin-glycoprotein complex and partially prevents dystrophy. Hum. Mol. Genet. 11, 1095-1105.
321. Wasala, N. B., Bostick, B., Yue, Y. and Duan, D. (2013). Exclusive skeletal muscle correction does not modulate dystrophic heart disease in the aged mdx model of Duchenne cardiomyopathy. Hum. Mol. Genet. 22, 2634-2641.
322. Wein, N., Vulin, A., Falzarano, M. S., Szigyarto, C. A., Maiti, B., Findlay, A., Heller, K. N., Uhlén, M., Bakthavachalu, B., Messina, S. et al. (2014). Translation from a DMD exon 5 IRES results in a functional dystrophin isoform that attenuates dystrophinopathy in humans and mice. Nat. Med. 20, 992-1000.
323. Wells, D. J., Wells, K. E., Asante, E. A., Turner, G., Sunada, Y., Campbell, K. P., Walsh, F. S. and Dickson, G. (1995). Expression of human full-length and minidystrophin in transgenic mdx mice: implications for gene therapy of Duchenne muscular dystrophy. Hum. Mol. Genet. 4, 1245-1250.
324. Wentink, G. H., van der Linde-sipman, J. S., Meijer, A. E. F. H., Kamphuisen, H. A. C., van Vorstenbosch, C. J. A. H. V., Hartman, W. and Hendriks, H. J. (1972). Myopathy with a possible recessive X-linked inheritance in a litter of Irish Terriers. Vet. Pathol. 9, 328-349.
325. West, N. A., Yang, M. L., Weitzenkamp, D. A., Andrews, J., Meaney, F. J., Oleszek, J., Miller, L. A., Matthews, D. and DiGuiseppi, C. (2013). Patterns of growth in ambulatory males with Duchenne muscular dystrophy. J. Pediatr. 163, 1759-1763 e1.
326. Winand, N. J., Edwards, M., Pradhan, D., Berian, C. A. and Cooper, B. J. (1994a). Deletion of the dystrophin muscle promoter in feline muscular dystrophy. Neuromuscul. Disord. 4, 433-445.
327. Winand, N. J., Pradhan, D. and Cooper, B. J. (1994b). Molecular characterization of severe Duchenne-type muscular dystrophy in a family of Rottweiler dogs. In Molecular Mechanism of Neuromuscular Disease. Tucson, AZ: Muscular Dystrophy Association.
328. Wood, M. J. (2013). To skip or not to skip: that is the question for Duchenne muscular dystrophy. Mol. Ther. 21, 2131-2132.
329. Wu, B., Moulton, H. M., Iversen, P. L., Jiang, J., Li, J., Li, J., Spurney, C. F., Sali, A., Guerron, A. D., Nagaraju, K. et al. (2008). Effective rescue of dystrophin improves cardiac function in dystrophin-deficient mice by a modified morpholino oligomer. Proc. Natl. Acad. Sci. USA 105, 14814-14819.
330. Wu, B., Li, Y., Morcos, P. A., Doran, T. J., Lu, P. and Lu, Q. L. (2009). Octa-guanidine morpholino restores dystrophin expression in cardiac and skeletal muscles and ameliorates pathology in dystrophic mdx mice. Mol. Ther. 17, 864-871.
331. Wu, B., Xiao, B., Cloer, C., Shaban, M., Sali, A., Lu, P., Li, J., Nagaraju, K., Xiao, X. and Lu, Q. L. (2011). One-year treatment of morpholino antisense oligomer improves skeletal and cardiac muscle functions in dystrophic mdx mice. Mol. Ther. 19, 576-583.
332. Xu, R., Camboni, M. and Martin, P. T. (2007). Postnatal overexpression of the CT GalNAc transferase inhibits muscular dystrophy in mdx mice without altering muscle growth or neuromuscular development: evidence for a utrophin-independent mechanism. Neuromuscul. Disord. 17, 209-220.
333. Yamamoto, K., Yamada, D., Kabuta, T., Takahashi, A., Wada, K. and Sekiguchi, M. (2010). Reduction of abnormal behavioral response to brief restraint by information from other mice in dystrophin-deficient mdx mice. Neuromuscul. Disord. 20, 505-511.
334. Yang, H. T., Shin, J. H., Hakim, C. H., Pan, X., Terjung, R. L. and Duan, D. (2012). Dystrophin deficiency compromises force production of the extensor carpi ulnaris muscle in the canine model of Duchenne muscular dystrophy. PLoS ONE 7, e44438.
335. Yin, H., Moulton, H. M., Seow, Y., Boyd, C., Boutilier, J., Iverson, P. and Wood, M. J. (2008). Cell-penetrating peptide-conjugated antisense oligonucleotides restore systemic muscle and cardiac dystrophin expression and function. Hum. Mol. Genet. 17, 3909-3918.
336. Yin, H., Saleh, A. F., Betts, C., Camelliti, P., Seow, Y., Ashraf, S., Arzumanov, A., Hammond, S., Merritt, T., Gait, M. J. et al. (2011). Pip5 transduction peptides direct high efficiency oligonucleotide-mediated dystrophin exon skipping in heart and phenotypic correction in mdx mice. Mol. Ther. 19, 1295-1303.
337. Yokota, T., Lu, Q. L., Partridge, T., Kobayashi, M., Nakamura, A., Takeda, S. and Hoffman, E. (2009). Efficacy of systemic morpholino exon-skipping in Duchenne dystrophy dogs. Ann. Neurol. 65, 667-676.
338. Yoshimura, M., Sakamoto, M., Ikemoto, M., Mochizuki, Y., Yuasa, K., Miyagoe-Suzuki, Y. and Takeda, S. (2004). AAV vector-mediated microdystrophin expression in a relatively small percentage of mdx myofibers improved the mdx phenotype. Mol. Ther. 10, 821-828.
339. Yuasa, K., Yoshimura, M., Urasawa, N., Ohshima, S., Howell, J. M., Nakamura, A., Hijikata, T., Miyagoe-Suzuki, Y. and Takeda, S. (2007). Injection of a recombinant AAV serotype 2 into canine skeletal muscles evokes strong immune responses against transgene products. Gene Ther. 14, 1249-1260.
340. Yue, Y., Li, Z., Harper, S. Q., Davisson, R. L., Chamberlain, J. S. and Duan, D. (2003). Microdystrophin gene therapy of cardiomyopathy restores dystrophinglycoprotein complex and improves sarcolemma integrity in the mdx mouse heart. Circulation 108, 1626-1632.
341. Yue, Y., Skimming, J. W., Liu, M., Strawn, T. and Duan, D. (2004). Full-length dystrophin expression in half of the heart cells ameliorates beta-isoproterenol-induced cardiomyopathy in mdx mice. Hum. Mol. Genet. 13, 1669-1675.
342. Yue, Y., Ghosh, A., Long, C., Bostick, B., Smith, B. F., Kornegay, J. N. and Duan, D. (2008). A single intravenous injection of adeno-associated virus serotype-9 leads to whole body skeletal muscle transduction in dogs. Mol. Ther. 16, 1944-1952.
343. Yugeta, N., Urasawa, N., Fujii, Y., Yoshimura, M., Yuasa, K., Wada, M. R., Nakura, M., Shimatsu, Y., Tomohiro, M., Takahashi, A. et al. (2006). Cardiac involvement in Beagle-based canine X-linked muscular dystrophy in Japan (CXMDJ): electrocardiographic, echocardiographic, and morphologic studies. BMC Cardiovasc. Disord. 6, 47.
344. Zatz, M., Pavanello, R. C., Lazar, M., Yamamoto, G. L., Lourenço, N. C., Cerqueira, A., Nogueira, L. and Vainzof, M. (2014). Milder course in Duchenne patients with nonsense mutations and no muscle dystrophin. Neuromuscul. Disord. 24, 986-989.
345. Zhang, Y. and Duan, D. (2012). Novel mini-dystrophin gene dual adeno-associated virus vectors restore neuronal nitric oxide synthase expression at the sarcolemma. Hum. Gene Ther. 23, 98-103.
346. Zhang, Y., Yue, Y., Li, L., Hakim, C. H., Zhang, K., Thomas, G. D. and Duan, D. (2013). Dual AAV therapy ameliorates exercise-induced muscle injury and functional ischemia in murine models of Duchenne muscular dystrophy. Hum. Mol. Genet. 22, 3720-3729.
347. Zhou, L., Rafael-Fortney, J. A., Huang, P., Zhao, X. S., Cheng, G., Zhou, X., Kaminski, H. J., Liu, L. and Ransohoff, R. M. (2008). Haploinsufficiency of utrophin gene worsens skeletal muscle inflammation and fibrosis in mdx mice. J. Neurol. Sci. 264, 106-111.
348. Zucconi, E., Valadares, M. C., Vieira, N. M., Bueno, C. R., Jr, Secco, M., Jazedje, T., da Silva, H. C., Vainzof, M. and Zatz, M. (2010). Ringo: discordance between the molecular and clinical manifestation in a golden retriever muscular dystrophy dog. Neuromuscul. Disord. 20, 64-70.